A study investigating the use of lard-derived diacylglycerol (DG) as a fat replacer on the flavor characteristics of frankfurters detected 50 volatile compounds in the samples analyzed using gas ...

The FDA has granted regular approval to rucaparib (Rubraca) for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant ...

A research group at the Italian Institute of Technology (IIT-Istituto Italiano di Tecnologia) has identified a candidate ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

The ultimate goal of materials scientists is to design and create materials with precise structures and tailored properties.

The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...

The treatment combination was previously approved in BRCA2m-positive patients with metastatic castrate-resistant prostate cancer.

RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...

A major Chinese clinical study on ovarian cancer has been published in CA: A Cancer Journal for Clinicians, one of the world's highest-impact medical journal, marking a first for a Chinese ...

The ICMR has funded the IPIROC study to evaluate a cost-effective dosing strategy for PARP inhibitor rucaparib in ovarian cancer patients, aiming to enhance access and reduce side effects.

The agency said that although Akeega with prednisone improved outcomes in all patients with HRR mutations, the benefits were driven by those with BRCA2 mutations.

The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus Akeega (abiraterone acetate) and prednisone ...